Publication:
NOL4 is a novel nuclear marker of small cell carcinoma and other neuroendocrine neoplasms

Thumbnail Image
Files
Lee-37-1091-1098-2022.pdf(3.01 MB)
Date
2022
relationships.isAuthorOfPublication
relationships.isSecondaryAuthorOf
relationships.isDirectorOf
Authors
Lee, Jung Hee ; Shin, Dong Hoon ; Lee, Sang Yull ; Park, Jun Young ; Kim, So Young ; Hwang, Chung Su ; Lee, Hyun Jung ; Na, Joo Young ; Kim, Jee Yeon
item.page.secondaryauthor
item.page.director
Publisher
Universidad de Murcia, Departamento de Biologia Celular e Histiologia
publication.page.editor
publication.page.department
DOI
https://doi.org/10.14670/HH-18-540
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Neuroendocrine neoplasms (NENs) such as small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) have characteristic histologies, but immunohistochemistry using neuroendocrine markers is still desirable to confirm diagnosis. CD56 is the most sensitive marker, but also stains various normal tissues and other tumors. Recently, we reported that nucleolar protein 4 (NOL4) is present in the blood of SCLC patients and found it was stained in the SCLC nuclei. In this study, we compared expressions of NOL4 and CD56, using 64 cases of SCLC, 18 cases of LCNEC, 6 cases of atypical carcinoid tumor, 7 cases of typical carcinoid tumor, 68 cases of lung adenocarcinoma, and 62 cases of lung squamous cell carcinoma. For primary lung NENs, sensitivity, specificity, positive predictive value (PPV) and negative predictive value of NOL4 were 77.5%, 95.8%, 93.2%, and 85.1%, respectively, while those of CD56 were 92.1%, 93.3%, 91.1%, and 94.1%. The specificity and PPV of NOL4 were higher than those of CD56, although the differences were not statistically significant. However, NOL4 retains its nuclear immunoreactivity in areas of crush artifact or necrosis. Furthermore, NOL4 was not expressed in adjacent normal tissues including bronchial cells and pneumocytes. Therefore, a combination of NOL4 staining with other cytoplasmic or membranous neuroendocrine markers might enhance diagnostic utility for SCLC and other NENs.
publication.page.subject
Neuroendocrine , NOL4 , Small cell lung cancer , Biomarker
Citation
Histology and Histopathology Vol. 37, nĀŗ11 (2022)
URI
http://hdl.handle.net/10201/129127
item.page.embargo
Collections
Histology and histopathology Vol.37,nĀŗ11 (2022)
Ir a EstadĆ­sticas